Acceleron Pharma Inc. (XLRN) News
Filter XLRN News Items
XLRN News Results
|Loading, please wait...|
XLRN News Highlights
- For XLRN, its 30 day story count is now at 37.
- Over the past 28 days, the trend for XLRN's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- LAW, MRK and RARE are the most mentioned tickers in articles about XLRN.
Latest XLRN News From Around the Web
Below are the latest news stories about Acceleron Pharma Inc that investors may wish to consider to help them evaluate XLRN as an investment opportunity.
Sphinx Trading LP Takes $120,000 Position in Acceleron Pharma Inc. (NASDAQ:XLRN)
Sphinx Trading LP bought a new stake in shares of Acceleron Pharma Inc. (NASDAQ:XLRN) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 700 shares of the biopharmaceutical companys stock, valued at approximately $120,000. Several other large investors also recently added to or reduced 
Merck Closes Biggest Biotech Deal of the Year
The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.
Merck completes tender offer for $11B Acceleron Pharma acquisition
No summary available.
Acceleron Pharma (NASDAQ:XLRN) vs. Brickell Biotech (NASDAQ:BBI) Head to Head Comparison
Acceleron Pharma (NASDAQ:XLRN) and Brickell Biotech (NASDAQ:BBI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk. Insider and Institutional Ownership 90.4% of Acceleron Pharma shares are owned by institutional investors. Comparatively, 14.2% 
Fulton Bank N.A. Buys Shares of 1,507 Acceleron Pharma Inc. (NASDAQ:XLRN)
Fulton Bank N.A. bought a new stake in Acceleron Pharma Inc. (NASDAQ:XLRN) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,507 shares of the biopharmaceutical companys stock, valued at approximately $260,000. Other institutional investors and hedge funds have also recently made changes to 
Merck says HSR waiting period for Acceleron Pharma deal expires
No summary available.
Acceleron Pharma Target of Unusually Large Options Trading (NASDAQ:XLRN)
Acceleron Pharma Inc. (NASDAQ:XLRN) was the target of some unusual options trading on Wednesday. Investors acquired 14,539 call options on the company. This is an increase of 589% compared to the average volume of 2,110 call options. In other news, SVP Adam M. Veness sold 6,650 shares of the firms stock in a transaction that 
Acceleron Pharma Inc. (NASDAQ: XLRN): Dont Ditch XLRN Stock In 2021
In the latest trading session, 3.34 million Acceleron Pharma Inc. (NASDAQ:XLRN) shares changed hands as the companys beta touched 0.11. With the companys most recent per share price at $179.81 changing hands around $5.83 or 3.35% at last look, the market valuation stands at $10.64B. XLRNs current price is a discount, trading about -5.66% off Acceleron Pharma Inc. (NASDAQ: XLRN): Dont Ditch XLRN Stock In 2021 Read More »
These 40 Mass. companies made the new Deloitte Fast 500 list
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
Merck Is a Dividend Play Ready to Get Back in Gear
Pfizer has been beating MRK stock in 2021, but that relative performance may reverse next year, with new drugs and acquisitions ahead.